All In Biotech

Free tool

FAERS Monitor: Savaysa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206316 or its brand name (Savaysa, Edoxaban Tosylate). Reports on generic versions are filed under their own applications.

Reports

6,825

Serious

6,132

90% of reports

Hospitalization

3,600

Death reported

899

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia329
  • off label use323
  • renal impairment295
  • dyspnoea274
  • cerebral infarction273
  • cardiac failure270
  • nausea247
  • atrial fibrillation226
  • pneumonia224
  • diarrhoea216
  • fall214
  • gastrointestinal haemorrhage207
  • acute kidney injury200
  • dizziness199
  • fatigue195

Reports by year received

View as table
YearReports
20101
2015345
2016253
2017130
201877
201996
2020119
2021569
20221,151
20231,178
20241,188
2025993
2026725

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,334 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cerebral infarctionSignal27334.831.08,842
renal impairmentSignal29510.99.72,631
cardiac failureSignal27010.49.22,285
gastrointestinal haemorrhageSignal2077.66.71,192
atrial fibrillationSignal2267.26.31,196
anaemiaSignal3295.34.81,159
acute kidney injurySignal2004.03.5456
pneumoniaSignal2242.11.9136
fall2142.01.7105
dyspnoea2741.51.345
dizziness1991.21.19
off label use3231.11.05
diarrhoea2161.00.90
nausea2471.00.90
fatigue1950.80.713

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.